3-(3-methoxy-phenyl)-3-(3-N,N-dimethylaminopropyl)-4,4-dimethyl-2,6-dioxopiperidine | 53873-21-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-(3-methoxy-phenyl)-3-(3-N,N-dimethylaminopropyl)-4,4-dimethyl-2,6-dioxopiperidine
• 英文别名: AGN 2979；3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethyl-2,6-piperidinedione；3-(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione；3-(m-methoxyphenyl)-3-(γ-N.N-dimethylaminopropyl)-4,4-dimethyl-2,6-dioxo-piperidine；3-[3-(dimethylamino)propyl]-3-(3-methoxyphenyl)-4,4-dimethylpiperidine-2,6-dione
• CAS: 53873-21-5
• 化学式: C₁₉H₂₈N₂O₃
• 分子量: 332.443
• InChiKey: UJFNSGBGJMRZKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  硫酸 、 3-(3-methoxy-phenyl)-3-(3-N,N-dimethylaminopropyl)-4,4-dimethyl-2,6-dioxopiperidine 在 乙醇 作用下， 以 乙醇 为溶剂， 以to yield AGN 2979 bisulphate as crystals的产率得到3(3-Methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethyl-piperidine-2,6-dione bisulphate
  参考文献：
  名称：

  Piperidin-2,6-dione bisulphate salts and their use for the treatment of stress related affective disorders

  摘要：

  某些3-苯基-3-二甲基氨基烷基-4,4-二甲基哌啶-2,6-二酮及其药理学上可接受的溶剂化物的新型双硫酸盐，在治疗或预防与压力相关的情感障碍，如焦虑、抑郁、偏头痛和睡眠呼吸暂停等方面，不会出现大鼠体重减轻和肝细胞变化，这限制了相应盐酸的允许临床剂量的边缘有效水平。首选的双硫酸盐是3（3,5-二甲氧基苯基）-3-（3-二甲基氨丙基）-4,4-二甲基哌啶-2,6-二酮双硫酸盐，特别是3（3-甲氧基苯基）-3-（3-二甲基氨丙基）-4,4-二甲基哌啶-2,6-二酮双硫酸盐。

  公开号：

  US07189742B2
• 作为产物：
  描述：

  4-(m-methoxyphenyl)-4-(γ-N,N-dimethylaminopropyl)-4-cyano-3,3-dimethyl-1-ethoxy-1-morpholino-but-1-ene 在 硫酸 作用下， 以 溶剂黄146 为溶剂， 生成 3-(3-methoxy-phenyl)-3-(3-N,N-dimethylaminopropyl)-4,4-dimethyl-2,6-dioxopiperidine
  参考文献：
  名称：

  Pharmacologically active pyridine derivatives

  摘要：

  在氢化吡啶环的4和5位置中至少有一个被C.sub.1-C.sub.4烷基或与至少4和5位置中的一个碳原子形成3至8个碳原子的碳环的双价基替代的3-苯基-3-氨基烷基-2,6-二酮四和六氢吡啶是具有药理学活性的新化合物，特别是具有中枢神经系统，特别是抗抑郁活性。4-氨基-烷基-4-氰基-4-苯基-丁酸和丁-2-烯酸的烷基酯，二烷基酰胺和杂环酰胺，在至少2和3位置中被C.sub.1-C.sub.4烷基或与至少2和3位置中的一个碳原子形成3至8个碳原子的碳环的双价烷基替代的新中间体参与制备上述药理活性化合物。揭示了几种制备药理活性化合物的方法。

  公开号：

  US03963729A1

文献信息

• [EN] PIPERIDIN-2,6-DIONE PAMOATE SALTS AND THEIR USE FOR THE TREATMENT OF STRESS-RELATED AFFECTIVE DISORDERS<br/>[FR] PAMOATES DE PIPERIDINE-2,6-DIONE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES AFFECTIFS EN LIAISON AVEC LE STRESS
  申请人：PRESTWICK PHARMACEUTICALS INC

  公开号：WO2004017970A1

  公开（公告）日：2004-03-04

  Novel pamoate salts of certain 3-phenyl-3-dimethylaminoalkyl-4,4dimethylpiperidin-2,6-diones (1) and pharmacologically acceptable solvates thereof are devoid of the weight loss and hepatocyte changes in the rat which limited to marginally effective levels the permitted clinical doses of the corresponding hydrochlorides in the treatment or prophylaxis of stress-related affective disorders such as anxiety, depression, migraine and sleep apnoea. The preferred pamoate salts are 3(3,5dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate and, especially, 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine2,6-dione pamoate.

  某些3-苯基-3-二甲基氨基烷基-4,4-二甲基哌啶-2,6-二酮（1）的帕莫酸盐及其药学上可接受的溶剂化物，在治疗或预防压力相关情感障碍，如焦虑、抑郁、偏头痛和睡眠呼吸暂停中，不会出现大鼠体重减轻和肝细胞变化，这限制了相应盐酸的允许临床剂量的边缘有效水平。首选的帕莫酸盐是3（3,5-二甲氧基苯基）-3-（3-二甲基氨丙基）-4,4-二甲基哌啶-2,6-二酮帕莫酸盐，尤其是3（3-甲氧基苯基）-3-（3-二甲基氨丙基）-4,4-二甲基哌啶-2,6-二酮帕莫酸盐。
• Conjugate addition
  申请人：Aspro-Nicholas Limited

  公开号：US03935207A1

  公开（公告）日：1976-01-27

  Organic compounds are prepared by a novel method of conjugate addition in which a donor compound including a carbanion derived from an activated methylidyne group is treated with an acceptor compound including a carbon-carbon unsaturated bond conjugated with an onium ion derived from a polar functional group. The method has particular application as a step in the production of novel intermediates and novel pharmacologically active compounds as disclosed in the Applicants' co-pending application of even date.

  有机化合物通过一种新颖的共轭加成方法制备，其中包括从活性甲基烯基群衍生的碳负离子的给体化合物与包括与极性功能基衍生的离子结构共轭的碳-碳不饱和键的受体化合物相结合。该方法特别适用于作为生产新型中间体和新型药理活性化合物的步骤，如申请人的同日申请中所披露。
• Novel piperidin-2,6-dione disulphate salts and their use for the treatment of stress related affective disorders
  申请人：——

  公开号：US20040249159A1

  公开（公告）日：2004-12-09

  Novel bisulphate salts of certain 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-diones and pharmacologically acceptable solvates thereof are devoid of the weight loss and hepatocyte changes in the rat which limited to marginally effective levels the permitted clinical doses of the corresponding hydrochlorides in the treatment or prophylaxis of stress-related affective disorders such as anxiety, depression, migraine and sleep apnoea. The preferred bisulphate salts are 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione bisulphate and, especially, 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione bisulphate.

  某些3-苯基-3-二甲氨基烷基-4,4-二甲基哌啶-2,6-二酮的新型双硫酸盐及其药学可接受的溶剂化合物不会出现大鼠体重减轻和肝细胞变化，这种变化限制了相应盐酸盐在治疗或预防压力相关情感障碍（如焦虑、抑郁、偏头痛和睡眠呼吸暂停）中允许的临床剂量的有效水平。首选的双硫酸盐为3（3,5-二甲氧基苯基）-3-（3-二甲基氨基丙基）-4,4-二甲基哌啶-2,6-二酮双硫酸盐，尤其是3（3-甲氧基苯基）-3-（3-二甲基氨基丙基）-4,4-二甲基哌啶-2,6-二酮双硫酸盐。
• Piperidin-2, 6-dione pamoate salts and their use for the treatment of affective disorders
  申请人：Wermuth Camille Georges

  公开号：US20090182012A1

  公开（公告）日：2009-07-16

  Novel pamoate salts of certain 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-diones and pharmacologically acceptable solvates thereof are devoid of the weight loss and hepatocyte changes in the rat which limited to marginally effective levels the permitted clinical doses of the corresponding hydrochlorides in the treatment or prophylaxis of stress-related affective disorders such as anxiety, depression, migraine and sleep apnoea. The preferred pamoate salts are 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate and, especially, 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.

  某些3-苯基-3-二甲基氨基烷基-4,4-二甲基哌啶-2,6-二酮的帕莫酸盐和药理学上可接受的溶剂化物，与相应的盐酸盐治疗或预防与压力有关的情感障碍，如焦虑、抑郁、偏头痛和睡眠呼吸暂停症，相比之下，不会出现大鼠的体重减轻和肝细胞改变，这些改变限制了相应的盐酸盐在治疗或预防这些疾病时的有效剂量。首选的帕莫酸盐是3（3,5-二甲氧基苯基）-3-（3-二甲基氨丙基）-4,4-二甲基哌啶-2,6-二酮帕莫酸盐，尤其是3（3-甲氧基苯基）-3-（3-二甲基氨丙基）-4,4-二甲基哌啶-2,6-二酮帕莫酸盐。
• Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of chronic abnormally high brain levels of serotonin or 5-hydroxy-indoleacetic acid, and in the treatment of bacterial or viral infections
  申请人：BRITISH TECHNOLOGY GROUP LIMITED

  公开号：EP0216555A2

  公开（公告）日：1987-04-01

  Phenyl-3-aminoalkyl-4-methyl-2,6-dioxopiperidines of the Formula I wherein: R1 represents methoxy, ethoxy or hydroxy, R2 represents methoxy, ethoxy. hydroxy or hydrogen; each R3 independently represents methyl or ethyl; R4 represents hydrogen or methyl; R5 represents hydrogen or methyl; and n represents 2 or 3, and a pharmacologically acceptable acid addition salt thereof (a) have anxiolytic activity, (b) antagonize the anxiogenic activity of benzodiazepine inverse agonists. (c) reducechronic abnormally high brain levels of serotonin or its metabolite 5-hydroxy-indoleacetic acid and (d) have antibacterial and antiviral activity. These activities are believed to be related to a reduction in serotonin turnover caused by blocking the depolarisation activation of tryptophan hydroxylase. Novel compositions comprise the compounds with a benzodiazepine agonist or benzodiazepine inverse agonist.

  式 I 的苯基-3-氨基烷基-4-甲基-2,6-二氧代哌啶类化合物 其中 R1 代表甲氧基、乙氧基或羟基、 R2 代表甲氧基、乙氧基、羟基或氢 每个 R3 独立地代表甲基或乙基 R4 代表氢或甲基 R5 代表氢或甲基；以及 n 代表 2 或 3、 及其药理上可接受的酸加成盐 (a) 具有抗焦虑活性，(b) 可拮抗苯并二氮杂卓反向激动剂的致焦虑活性。(c) 降低大脑中血清素或其代谢物 5-羟基吲哚乙酸的长期异常高水平；以及 (d) 具有抗菌和抗病毒活性。据信，这些活性与通过阻断色氨酸羟化酶的去极化活化而导致的血清素周转减少有关。新型组合物由这些化合物与苯并二氮杂卓激动剂或苯并二氮杂卓反向激动剂组成。